Clinical-stage biotech Moderna (NASDAQ:MRNA) announced yesterday that it had published an interim analysis of its mRNA-1273 vaccine candidate in The New England Journal of Medicine that showed promising results."We believe that either a vaccine or effective treatment is needed before people will feel fully comfortable traveling the way they did before the pandemic started," Booking Holdings CEO Glenn Fogel said on the last earnings call in May.